Skip to content
AnalystLens

Teva Pharmaceutical Industries 8-K Report, Financial Results (Jul 29, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 29, 2026
Period End
July 29, 2026
Security
TEVA
In the record · 2016–202610-K1110-Q278-K283

TEVA filed 11 annual reports (10-K), 27 quarterly reports (10-Q) and 283 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Aug ’19Aug ’19
  2. Leadership change8-K · Jul ’21Jul ’21
  3. Material agreement8-K · May ’25May ’25

01—Abstract

Summary

Summary of the 8-K filed July 29, 2026. Cited figures are marked; the original filing is the authoritative source.

Teva Pharmaceutical Industries Limited reported second-quarter 2026 results, with revenues of $4,142 milliona, down 1% in U.S. dollars and 3% in local currency year-over-year, mainly due to lower generics revenues, particularly lenalidomide capsules in the U.S. Key innovative brands AUSTEDO, AJOVY and UZEDY collectively generated over $1 billion in revenues, growing 43% year-over-year in local currency, and Teva raised its 2026 revenue outlook for all three.

The company recorded a GAAP net loss attributable to Teva of $576 millionb, or $0.49 per share, driven by $724 million of acquired IPR&D related to the acquisition of Emalex Biosciences and its ecopipam (EBS-101) asset, which was acquired for approximately $700 million in cash. Non-GAAP diluted EPS was $0.02, including a ($0.61) per share impact from the Emalex acquisition. Teva's 2026 outlook calls for revenues of $16.5 to $16.85 billion, non-GAAP operating income of $3.8 to $4.0 billion, and free cash flow of $2.0 to $2.4 billion, with earnings and cash flow guidance maintained while the revenue outlook was raised for the innovative brands.

Second-quarter free cash flow was $622 millionc, and total debt was $16,593 million at June 30, 2026, with the short-term portion rising to 27% of total debt. The filing also announces that the company will replace its American Depositary Share program with a direct listing of its ordinary shares on the NYSE, with trading beginning September 14, 2026.

02—Key points

Key Highlights

  1. Revenues of $4,142 million, down 1% in U.S. dollars and 3% in local currency year-over-year, mainly due to lower lenalidomide capsule revenues in the U.S.
  2. AUSTEDO ($696 million), AJOVY ($244 million) and UZEDY ($77 million) collectively exceeded $1 billion in quarterly revenues, growing 43% year-over-year in local currency; 2026 revenue outlook was raised for all three brands.
  3. GAAP net loss attributable to Teva of $576 million ($0.49 per share), including $726 million of Emalex-related expenses; non-GAAP diluted EPS was $0.02.
  4. Operating loss of $231 million versus operating income of $455 million a year earlier; non-GAAP operating income was $375 million, a 9.0% margin versus 27.1% in Q2 2025, mainly due to higher R&D tied to ecopipam.
  5. Free cash flow of $622 million and operating cash flow of $411 million in Q2 2026.
  6. 2026 outlook: revenues of $16.5 to $16.85 billion, non-GAAP operating income of $3.8 to $4.0 billion and free cash flow of $2.0 to $2.4 billion, with earnings and cash flow guidance maintained.
  7. ADS program to be replaced by a direct NYSE listing of ordinary shares, with trading commencing September 14, 2026; Fitch raised Teva's corporate credit rating to Investment Grade BBB-.

03—Questions

Frequently Asked Questions

  1. Why did Teva report a GAAP loss in the second quarter of 2026?

    The GAAP loss was driven primarily by $724 million of acquired IPR&D from the acquisition of Emalex Biosciences and its primary asset, ecopipam (EBS-101), which the filing says contributed $0.61 per share in negative impact. Total R&D expenses rose to $970 million from $244 million a year earlier, mainly due to this acquisition.

  2. How did the key innovative brands perform?

    AUSTEDO generated global revenues of $696 million, growing 40% year-over-year in local currency; AJOVY generated $244 million, up 56%; and UZEDY generated $77 million, up 43%. Together they exceeded $1 billion in revenues, and Teva raised its 2026 revenue outlook for each brand, now expecting combined 2026 revenue of about $3.7 billion.

  3. What is the outlook for 2026?

    Teva expects 2026 revenues of $16.5 to $16.85 billion, non-GAAP operating income of $3.8 to $4.0 billion including about $0.77 billion of Emalex-related expenses, non-GAAP diluted EPS of $1.91 to $2.11, and free cash flow of $2.0 to $2.4 billion. Earnings and cash flow outlook were maintained, while the innovative brand revenue outlook was increased.

  4. What is changing with Teva's listing?

    Teva is replacing its American Depositary Share program with a direct listing of its ordinary shares on the NYSE. ADSs will be exchanged one-for-one for ordinary shares, which will begin trading on the NYSE on September 14, 2026, after ADSs cease trading at the close on September 11, 2026. The company says the transition aims to broaden its shareholder base, support potential index inclusion and optimize its cost of capital. Tel Aviv Stock Exchange trading is not affected.

  5. How is Teva's debt position?

    Total debt was $16,593 million as of June 30, 2026, compared with $16,807 million at December 31, 2025, mainly due to $201 million of exchange rate fluctuations. Short-term debt represented 27% of total debt, up from 11% at year-end 2025, and average debt maturity was about 5.1 years. Financial leverage was 68%.

04—Continue

← View all 8-K filings